FILING ANALYSIS · FRIDAY, NOVEMBER 13
Jade Biosciences, Inc. JBIO — 8-K: Results of Operations and Financial Condition
neutral
Jade Biosciences reported a net loss of $35.1 million for the third quarter, with cash and investments of $476 million expected to provide a runway into the fourth quarter of 2028, and multiple clinical catalysts expected in 2027, including the initiation of a Phase 3 trial for JADE101 and interim data for JADE101 and JADE201, but no significant quantified surprises were disclosed
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →